Advanced search
Publication Cover
Immunotherapy Volume 13, 2021 - Issue 5
Submit an article Journal homepage
247
Views
0
CrossRef citations to date
0
Altmetric
Case Series

PD-L1 ≥ 50% Lung Cancer Refractory to PD-1 Inhibition: The Role of Salvage Chemo-Immunotherapy Combination

Francesco Gelsomino1 Divisione di Oncologia medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 13 Bologna, 40138, ItaliaView further author information
,
Francesco Facchinetti2 Université Paris-Saclay, Institut Gustave Roussy, Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 114 Rue Edouard Vaillant, Villejuif94800, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6313-6341View further author information
ORCID Icon,
Monia Sisi3 Department of Experimental, Diagnostic & Specialty Medicine, Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 13Bologna, 40138, ItalyView further author information
,
Teresa Zielli4 Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14Parma, 43126, ItalyView further author information
,
Marcello Tiseo4 Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14Parma, 43126, Italy;5 Department of Medicine & Surgery, University of Parma, Via Gramsci 14Parma, 43126, ItalyView further author information
&
Andrea Ardizzoni1 Divisione di Oncologia medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 13 Bologna, 40138, Italia;3 Department of Experimental, Diagnostic & Specialty Medicine, Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 13Bologna, 40138, ItalyView further author information
Pages 363-369 | Received 21 Oct 2020, Accepted 19 Jan 2021, Published online: 03 Feb 2021

References

  • Reck M , Rodríguez-AbreuD , RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
  • Mok TSK , WuY-L , KudabaIet al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet393(10183), 1819–1830 (2019).
  • Gandhi L , Rodríguez-AbreuD , GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med.378(22), 2078–2092 (2018).
  • Paz-Ares L , LuftA , VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
  • Garon EB , HellmannMD , RizviNAet al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study. J. Clin. Oncol.37(28), 2518–2527 (2019).
  • Mezquita L , AuclinE , FerraraRet al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol.4(3), 351–357 (2018).
  • Aguilar EJ , RicciutiB , GainorJFet al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol.30(10), 1653–1659 (2019).
  • Tambo Y , SoneT , ShibataKet al. Real-world efficacy of first-line pembrolizumab in patients with advanced or recurrent non-small-cell lung cancer and high PD-L1 tumor expression. Clin. Lung Cancer21(5), e366–e379 (2020).
  • Miyawaki T , KenmotsuH , MoriKet al. Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non–small-cell lung cancer. Clin. Lung Cancer21(5), e405–e414 (2020).
  • Derosa L , HellmannMD , SpazianoMet al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol.29(6), 1437–1444 (2018).
  • Arbour KC , MezquitaL , LongNet al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J. Clin. Oncol.36(28), 2872–2878 (2018).
  • Kawachi H , TamiyaM , TamiyaAet al. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Invest. New Drugs38(1), 211–218 (2020).
  • Shibaki R , MurakamiS , ShinnoYet al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Thorac. Cancer10(4), 815–822 (2019).
  • Kang DH , ChungC , KimJOet al. Pleural or pericardial metastasis: a significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. Thorac. Cancer9(11), 1500–1508 (2018).
  • Leonetti A , WeverB , MazzaschiGet al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist. Updat.46, 100644 (2019).
  • Vera Aguilera J , PaludoJ , McWilliamsRRet al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res.30(4), 364–375 (2020).
  • Rossi C , GilhodesJ , MaerevoetMet al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. Am. J. Hematol. (2018) doi:10.1002/ajh.25154 ( Epub ahead of print).
  • Garcia CA , DacicSVL. Disease response with the addition of platinum-based chemotherapy to pembrolizumab after progression on pembrolizumab monotherapy in PD-L1-expressing non-small cell lung cancer. J. Thorac. Oncol.13(8), e135–136 (2018).
  • Ackermann CJ , ReckM , Paz-AresL , BarlesiF , CalifanoR. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: travelling at the speed of light. Lung Cancer134, 245–253 (2019).
  • Proto C , FerraraR , SignorelliDet al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat. Rev.75, 39–51 (2019).
  • Prelaj A , TayR , FerraraR , ChaputN , BesseB , CalifanoR. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur. J. Cancer106, 144–159 (2019).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.